The thalidomide disaster, lessons from the past

Methods in Molecular Biology

Volumn 947, Issue , 2013, Pages 575-586

  Ridings, James E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Teratology; Thalidomide

Indexed keywords

EID: 84871895409     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-131-8_36     Document Type: Article

References (22)

1. Banerjee U, Geh SL (1976) A comparative study of several methods for recording spontaneous motor activity in mice under drug effects. Indian J Physiol Pharmacol 20:53-58
2. Burley DM, Dennison TC, Harrison W (1959) Clinical experience with a new sedative drug. Practitioner 183:57-61
3. Kingsley P et al (1979) Suffer the children: the story of thalidomide, the insight team of the Sunday times (UK). Futura Publications Ltd, London
4. Sjostrom H (1972) Thalidomide and the power of the drug companies. Penguin, Harmondsworth
5. Collins FS et al (1998) Guidelines for evaluation of reproductive and developmental toxic-ity of food additives in females. Int J Toxicol 17:299-325
6. Wilson JG (1973) Environment and birth defects (environmental science series). Academic, London
7. Agranat I, Caner H, Caldwell J (2002) Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 1:753-768
8. Schardein J (1976) Drugs as teratogens. CRC, Cleveland
9. Briggs G, Freeman R, Yaffe S (2011) Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Williams and Wilkins, Lipencott
10. 12 in rabbits, rats and monkeys. Teratology 5:233-240
11. Collins T (2006) History of evolution of reproductive and developmental toxicology guidelines. Curr Pharm Des 12:1449-1465
12. The History of the International Conference of Harmonisation Guidelines (1990) http://www.ich.org/about/history.html. Accessed 19 Aug 2011
13. Norbert C (2010) Outsourcing in drug development. Drug Development, 48-49
14. European Paediatric Regulation (2006): Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Dec 2006, on Medicinal Products for Paediatric Use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC)
15. No. 726/2004. Official Journal L378, 27/12/2006, P001-0019
16. Stanford University Medical Center (2008) 14 Drugs identified as most urgently needing study for off-label use. ScienceDaily. http://www.science- daily.com/releases/2008/11/081124130939. htm. Accessed 17 Aug 2011
17. Horen B, Montastru JL, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label use in paediatric outpatients. Br J Clin Pharmacol 54:665-670
18. Clark R et al (2008) Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res B Dev Reprod Toxicol 83:397-406
19. Clark R (2009) Embryotoxicity of the artemisi-nin antimalarials and potential consequences for Use in women in thefirst trimester. Reprod Toxicol 28:285-296
20. World Health Organisation (2006) Assessment of the safety of artemisinin compounds in pregnancy. Report of two informal consultations convened by the special program for research and training in tropical diseases and the global malaria program of the World Health Organisation. WHO/CDS/MAL/20903.1094. WHO/GMP/TDR/Artemesinin/07.1.ISBN 978 92 4 159 611 4
21. Reuben B (2007) Contributory factors in recent drug disasters. http://Eyeforpharma. com. Accessed 18 Aug 2011
22. Drug Firms Hit by Safety Scares (2004) BBC News. http://news.bbc.co.uk/1/ hi/busi-ness/4025001.stm. Accessed 18 Aug 2011